Search results for "Highlights"
Semaglutide showed some benefit in patients with NASH, liver fibrosis
Significantly more patients taking the glucagon-like peptide-1 receptor agonist had resolution of their nonalcoholic steatohepatitis (NASH) than those taking placebo, but rates of liver fibrosis improvement were similar between groups, an industry-funded trial found.
https://gastroenterology.acponline.org/archives/2020/11/20/1.htm
20 Nov 2020
Guideline offers recommendations on anticoagulation, thromboses in vascular liver disorders
Among other guidance, the American College of Gastroenterology recommends anticoagulation for all patients without cirrhosis who have acute symptomatic portal vein thrombosis or mesenteric vein thrombosis in the absence of any contraindication.
https://gastroenterology.acponline.org/archives/2020/01/24/1.htm
24 Jan 2020
Use of drugs, nondrug treatments for functional bowel disorders analyzed
One study found that nonpharmacologic interventions are underused in ambulatory care visits for functional bowel disorders, while another found that patients with irritable bowel disease and their insurers have financial incentives to favor differing treatments.
https://gastroenterology.acponline.org/archives/2020/10/23/1.htm
23 Oct 2020
Study finds higher proportion of CRC diagnoses in patients under 50 since 2004
Based on the results, study authors suggested expanding colorectal cancer (CRC) screening to patients 45 years of age, but an accompanying editorial expressed concern that the risks could outweigh the benefits in the general population.
https://gastroenterology.acponline.org/archives/2019/07/26/2.htm
26 Jul 2019
Early-onset colorectal cancer increases sharply between ages 49 and 50, study finds
According to U.S. registry data, incidence of colorectal cancer increased 46.1% from age 49 years to age 50 years, from 34.9 to 51.0 per 100,000 population.
https://gastroenterology.acponline.org/archives/2020/02/28/1.htm
28 Feb 2020
Guidance issued for comanagement of COVID-19 GI, liver manifestations
Two meta-analyses, one of them from the American Gastroenterological Association (AGA), found that GI symptoms and liver abnormalities are not uncommon in patients with COVID-19. The AGA issued a series of best practice statements based on its findings.
https://gastroenterology.acponline.org/archives/2020/05/22/1.htm
22 May 2020
Combination therapy for IBD carries higher infection risk than monotherapy
Monotherapy for inflammatory bowel disease (IBD) with an immunosuppressive agent was associated with a lower risk of serious infection than a tumor necrosis factor (TNF) antagonist alone or an anti-TNF plus an immunosuppressive agent, according to a meta-analysis.
https://gastroenterology.acponline.org/archives/2019/03/22/2.htm
22 Mar 2019
Anti-TNF therapy did not reduce IBD hospitalizations or intestinal resections in Ontario
Infliximab may have been used inappropriately in Crohn's disease and underused in ulcerative colitis, according to the authors of an analysis of hospitalizations, intestinal resections, and drug costs related to inflammatory bowel disease (IBD).
https://gastroenterology.acponline.org/archives/2019/06/28/3.htm
28 Jun 2019
Spotlight on ulcerative colitis
In the past month, the American Gastroenterological Association published new recommendations, a meta-analysis compared first- and second-line treatments, and a study found a recent decrease in colorectal cancer incidence in patients with ulcerative colitis.
https://gastroenterology.acponline.org/archives/2020/01/24/5.htm
24 Jan 2020
COVID-19 guidance released for managing IBD patients, endoscopic procedures
The American Gastroenterological Association released new guidance for clinicians caring for patients with inflammatory bowel disease (IBD) and those performing endoscopic procedures, and two recent studies looked at GI symptoms in patients with COVID-19.
https://gastroenterology.acponline.org/archives/2020/04/24/1.htm
24 Apr 2020